Skip to content

EV / sales at other companies

Humana logo
HumanaHUM
0.2×-0.1×
CVS Health logo
CVS HealthCVS
0.2×0.0×
UnitedHealth Group logo
UnitedHealth GroupUNH
0.7×-0.6×
Alignment Healthcare logo
Alignment HealthcareALHC
0.8×-0.4×
Astrana Health logo
Astrana HealthASTH
0.6×-0.2×
Agilon Health logo
Agilon HealthAGL
-0×-0.3×

Other financials

Income statement

See full
Revenue$749.2M+62.0%
Operating income$27.3M+2,246%
Net income$27.3M+2,246%
EPS (diluted)$0.05

Balance sheet

See full
Cash & equivalents$173.3M+11.5%
Total debt$3.3M-0.9%
Total equity$339.4M+1.0%
Total assets$697.7M+19.5%

Cash flow

See full
Operating cash flow$107.9M+762%
CapEx$854.0K+362%
Free cash flow$107.0M+750%

Valuation

See full
Market cap$2.67B-49.7%
P/S1.2×-2.4×

Profitability

See full
Operating margin-2.6%+3.5pp
Net margin-2.6%+2.8pp
FCF margin-10.3%

Returns & leverage

See full
Return on equity-16.9%-170pp
Debt / equity0.0×
Current ratio1.3×-0.2×

Where this comes from

Calculated from Clover Health Investments’s reported figures.

Based on the most recent quarter.

The official record: Clover Health Investments’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Clover Health Investments's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Clover Health Investments's EV / sales?
Clover Health Investments (CLOV) reported EV / sales of 0.6× in Q4 2025.
How has Clover Health Investments's EV / sales changed year-over-year?
Clover Health Investments's EV / sales decreased by 41.5% year-over-year, from 1× to 0.6×.
What is the long-term trend for Clover Health Investments's EV / sales?
Over 4 years (2020 to 2025), Clover Health Investments's EV / sales has grown at a -50.0% compound annual growth rate (CAGR), from 9.4× to 0.6×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.